Frontier Pharma Parkinsons Disease - Identifying and Commercializing First-in-Class Innovation Analysis & Forecast.pdf

4.11 Efficacy and Safety of Marketed Products 31
4.12 Treatment Algorithm 33
4.13 Current Unmet Needs 35
5 Assessment of Pipeline Product Innovation 37
5.1 Parkinson’s Disease Pipeline by Molecule Type, Phase and Therapeutic Targets 37
5.2 Comparative Distribution of Programs between the Parkinson’s Disease Market and
Pipeline by Therapeutic Target Family 41
6 Signaling Network, Parkinson’s Disease Genetics and Innovation Alignment 46
6.1 The Complexity of Signaling Network in Central Nervous System 46
6.2 Signaling Pathways, Disease-Causing Mutations and First-in-Class Molecular Target
Integration 47
6.3 First-in-Class Target Matrix Assessment 51
7 First-in-Class Target and Pipeline Program Evaluation 54
7.1 Overview of Pipeline Programs Targeting ?-synuclein 54
7.2 Overview of Pipeline Programs Targeting LRRK2 57
7.3 Overview of Pipeline Programs Targeting Glial Cell-Derived Neurotrophic Factor 60
7.4 Overview of Pipeline Programs Targeting Progranulin 63
7.5 Overview of Pipeline Programs Targeting Cerebral Dopamine Neurotrophic Factor 66
7.6 Overview of Pipeline Programs Targeting Mesencephalic Astrocyte-Derived Neurotrophic
Factor 68
7.7 Overview of Pipeline Programs Targeting Tyrosine Receptor Kinase B 70
7.8 Overview of Pipeline Programs Targeting Metabotropic Glutamate Receptor 4 73